 AIM ImmunoTech Inc NYSE:AIM has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen rintatolimod in healthy subjects. Ampligen is an immuno-modulator with broad-spectrum activity being developed by AIM for globally important cancers, viral diseases and disorders of the immune system. 